澳大利亚的一项胰岛素自动给药系统（AID）试验结果和其他研究结果表明，使用 AID 可能对澳大利亚的许多 1 型糖尿病成人患者有益。

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Internal Medicine Journal Pub Date : 2024-11-27 DOI:10.1111/imj.16567

Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaac, Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed Loop Research Group

{"title":"澳大利亚的一项胰岛素自动给药系统（AID）试验结果和其他研究结果表明，使用 AID 可能对澳大利亚的许多 1 型糖尿病成人患者有益。","authors":"Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaac, Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed Loop Research Group","doi":"10.1111/imj.16567","DOIUrl":null,"url":null,"abstract":"<p>Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"55 1","pages":"148-153"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes\",\"authors\":\"Alicia J. Jenkins, Andrzej S. Januszewski, Adrienne Kirby, Christel Hendrieckx, Sybil A. McAuley, Melissa H. Lee, Barbora Paldus, Sara Vogrin, Martin I. de Bock, Mary B. Abraham, Leon A. Bach, Morton G. Burt, Neale D. Cohen, Peter G. Colman, Elizabeth A. Davis, D. J. Holmes-Walker, Joey Kaye, Anthony C. Keech, Kavita Kumareswaran, Richard J. MacIsaac, Roland W. McCallum, Catriona M. Sims, Jane Speight, Stephen N. Stranks, Vijaya Sundararajan, Steven Trawley, Glenn M. Ward, Timothy W. Jones, David N. O'Neal, for the Australian JDRF Closed Loop Research Group\",\"doi\":\"10.1111/imj.16567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.</p>\",\"PeriodicalId\":13625,\"journal\":{\"name\":\"Internal Medicine Journal\",\"volume\":\"55 1\",\"pages\":\"148-153\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imj.16567\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16567","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

只有不到 20% 的澳大利亚 1 型糖尿病（T1D）患者能达到建议的血糖目标。技术的使用与改善血糖有关，其中最先进的是胰岛素自动给药系统（AID），该系统现已被推荐为 T1D 护理的黄金标准。我们在澳大利亚进行的 AID 试验表明，许多患有 T1D 的成人都能达到推荐目标。包括生活经验数据在内的其他研究也对此表示支持。大多数澳大利亚成人 T1D 患者的胰岛素泵得不到补贴。我们主张改变这种状况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.